The Lancet· Tomoki Sakakida, Hiroya Taniguchi, Masako Asayama, Yusuke Suwa, Takaya Shimura, Seiichiro Mitani, Akitaka Makiyama, Hiroyuki Arai, Hiroshi Matsuoka, Mitsuru Yokota, Yoshinao Takano, Kyoko Kato, Hisanobu Oda, Takeshi Kajiwara, Kohei Ogawa, Nobuhiro Shibata, Kentaro Sawada, Takato Yomoda, Toshihiro Kudo, Hiroyuki Okuda, Yuta Okumura, Chihiro Tanaka, Masato Nakamura, Takashi Tsuda, Takahito Kitajima, Hiroshi Tsukuda, Eiji Shinozaki, Mitsuhiro Furuta, Tomomi Kashiwada, Koichi Okuya, Hiroyuki Mushiake, Junichi Hasegawa, Koei Nihei, Takashi Mizushima, Takashi Mine, Takuro Mizukami, Chiho Kudo, Ayako Mishima, Kenta Murotani, Toshiki Masuishi, PRABITAS investigators·· 4 hours agoPickScore77
[Articles] 14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan
In brief
The phase 3 PRABITAS trial showed that a 14-day schedule of trifluridine-tipiracil plus bevacizumab was non-inferior to the 28-day schedule for overall survival. The study was conducted in refractory metastatic colorectal cancer, and the 14-day schedule had lower haematological and gastrointestinal toxicity. The results support the simplified schedule as a new standard for this combination.
Why it matters
The phase 3 study directly compared 14-day versus 28-day schedules for overall survival non-inferiority and toxicity, informing schedule choice.
Source: The Lancet · thelancet.com